Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Increase in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 151,300 shares, a growth of 389.6% from the November 15th total of 30,900 shares. Currently, 1.7% of the shares of the stock are sold short. Based on an average trading volume of 1,740,000 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and issued a $7.00 price objective on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

Windtree Therapeutics Trading Up 2.3 %

WINT opened at $0.36 on Friday. Windtree Therapeutics has a twelve month low of $0.33 and a twelve month high of $14.75. The firm has a market capitalization of $3.24 million, a PE ratio of -0.02 and a beta of 0.54. The firm’s 50-day moving average price is $0.65 and its 200 day moving average price is $3.60.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.